Cellectis S.A. (CLLS) shares climbed 7.35 percent to $4.41, gaining $0.30 on Thursday, after the biotechnology company announced it is hosting an R&D Day in New York City. During the event, the company's leadership team and key opinion leaders are presenting the full Phase 1 dataset and outlining the pivotal Phase 2 trial design for its investigational therapy, lasme-cel.
The stock traded between $4.35 and $5.48 during the session, compared with a previous close of $4.11 on the Nasdaq. Volume reached about 1 million shares, well above the average of 0.17 million.
Over the past 52 weeks, Cellectis shares have traded between $1.10 and $5.48.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.